Trial Profile
An Exploratory Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Cotadutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors AstraZeneca; MedImmune
- 29 Jun 2021 Results assessing effect of Cotadutide on energy intake or energy expenditure in overweight and obese subjects presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 17 Jan 2020 Status changed from active, no longer recruiting to completed.
- 11 Dec 2019 Planned End Date changed from 27 Dec 2019 to 23 Dec 2019.